Medtronic Strengthens Global Structural Heart Leadership with Launch of Next-Gen Evolut FX+ TAVI System in India

Sep 10, 2025 11:06 CST Updated 11:06

Medtronic

Medical Device Manufacturer

Shanghai Event Registration:2025 Medical Device R&D Innovation Forum

September 9, 2025Medtronic(Medtronic, NYSE: MDT) announced today that it willThe Latest Generation Evolut FX+ Transcatheter Aortic Valve Implantation (TAVI) System Officially Introduced to the Indian Market. This product received approval from India's Central Drugs Standard Control Organization (CDSCO) in June this year, marking the entry into the Indian market as part of its structural heart disease treatment strategy. Prior to this, the Evolut FX+ had already obtainedFDA Approval in the United States and CE Certification in Europe, with global passport qualifications.

# Technical Highlights: Meet Current STENT Standards While Considering Future Intervention Needs

Improved Diamond Framework: Introducing three coronary access windows, with an area four times that of the previous Evolut system, providing excellent space and operational flexibility for potential subsequent coronary interventions.
Combining Structure and Performance: Although the channel design has been optimized, it does not weaken the valve hemodynamics, high radial force, or durability, maintaining the consistent performance level of the Evolut platform.
Globally certified: Approved by the FDA in March 2024, received CE marking in October 2024, and won CDSCO approval in India in June 2025. Global expansion is gradually being realized.

# Clinical Evidence: Real-World and Randomized Controlled Studies Support the Advantages of the Evolut Platform

SMART 2-Year Data: Demonstrates Superior Performance in Patients with Small Annuli

SMART Trial isThe FirstGlobal Large-Scale, Randomized Controlled Head-to-Head Study of Evolut vs. SAPIEN in Patients with Small Aortic Annuli. Data show that at two years of follow-up, Evolut TAVR demonstrated a significantly lower incidence of bioprosthetic valve dysfunction (BVD) compared to SAPIEN, with no significant difference in the composite endpoint (mortality, stroke, or rehospitalization).

Valve thrombosis incidenceReduced by approximately 5 times（p = 0.0048）
Incidence of Hemodynamic Structural Valve DysfunctionApproximately 9 times lower（p < 0.001）

Evolut Low-Risk 5-Year Data: TAVR Results Comparable to or Slightly Better Than Surgical Outcomes

The randomized study for patients with low surgical risk (Low-Risk Trial) showed that Evolut TAVR:

The rate of all-cause mortality or disabling stroke was comparable to surgery (TAVR: 15.5% vs Surgery: 16.4%, p = 0.47).
Tendency of cardiovascular death decreases (7.2% vs 9.3%，p = 0.15）
The effective orifice area of the valve is larger,Lower average transvalvular pressure gradient`, delaying the risk of calcification and thrombosis`

Real-world Data: Evolut FX Optimizes Implant Consistency and Complication Control

In the early application experience across multiple U.S. centers, the Evolut FX system demonstrated excellent valve alignment rates and complication control:

Coronary Artery Valve Alignment 95.8%
30-Day Mortality1.2%, Stroke Rate 1.8%
Mild Paravalvular Leak13.2%, no moderate to severe leakage, excellent hemodynamic performance

In addition, the Evolut FX system has demonstrated advantages such as smooth catheter advancement, reduced recaptures, and significant improvements in deployment symmetry and valve alignment in multi-center clinical investigations.

# Siyu MedTech Observation

"The Debut of a 'Future-Oriented' Holistic Treatment Strategy"

The optimized channel design of Evolut FX+ incorporates coronary accessibility into the structural valve implantation ecosystem, facilitating subsequent interventions for patients and demonstrating the design concept of "implant as a life management tool."

Solid clinical evidence empowers the product.

The research data from the SMART Trial and Low-Risk Trial provide reliable support for the safety and durability of the Evolut platform, particularly critical in younger, low-risk, and anatomically complex populations.

India's Implementation is of Strategic Significance

India's TAVI market is still in its infancy, and the introduction of Evolut FX+ means that local doctors will have access to more advanced treatment options, also driving the upgrade of devices in the field of structural heart disease.

Chinese manufacturers can learn from the concept of "structural optimization + future services"

If domestically produced interventional devices can balance precise execution during implantation with postoperative interventional continuity, while incorporating high-quality clinical research, they have the potential to break through in global competition.

Conclusion

Evolut FX+ Launches in India: A Technological Upgrade and MoreDisplay of Modular Treatment Concept Combined with Clinically Validated ResultsIn the future, with more clinical evidence being disclosed and global promotion deepening, the platform's innovation is expected to become a new benchmark in the field of structural interventions.

# Siyu MedTech Recommended Articles Collection

Medical Device Market Dynamics

▌Frontiers of Technology and Innovation Trends

Cardiovascular →Cardiovascular Intervention / Cardiac Ablation / Cardiac Rhythm Management / Renal Artery Sympathetic Denervation

Cerebrovascular →Cerebrovascular Intervention / Mechanical Thrombectomy

Orthopedics →Internal Fixation Devices / Artificial Joints / Spinal Fixation Systems / Rehabilitation Equipment

Ophthalmology →Phacoemulsification / Intraocular Lens / Glaucoma Drainage Device / Retinal Laser

Nervous System →Neurointervention/Neurostimulation

Endocrine System →Insulin Pump / Continuous Glucose Monitoring System / Hybrid Closed-Loop System

Digestive System →Endoscopic Intervention/Magnetically Controlled Capsule

Respiratory System →Respiratory Support/Sleep Apnea Monitoring

▌Corporate Financing and Strategic Acquisitions